Show simple item record

dc.contributor.authorJiménez-Vacas, J.M.
dc.contributor.authorGómez Gómez, Enrique
dc.contributor.authorMontero-Hidalgo, Antonio J.
dc.contributor.authorHerrero-Aguayo, V.
dc.contributor.authorL-López, Fernando
dc.contributor.authorSánchez-Sánchez, Rafael
dc.contributor.authorGuler, Ipek
dc.contributor.authorBlanca, Ana
dc.contributor.authorMéndez-Vidal, María José
dc.contributor.authorCarrasco, Julia
dc.contributor.authorLópez-Miranda, José
dc.contributor.authorRequena-Tapia, M.J.
dc.contributor.authorCastaño, Justo P.
dc.contributor.authorGahete Ortiz, Manuel D.
dc.contributor.authorLuque, Raúl M.
dc.date.accessioned2019-11-22T13:28:08Z
dc.date.available2019-11-22T13:28:08Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10396/19155
dc.description.abstractRecent data suggested that plasma Ghrelin O-Acyl Transferase enzyme (GOAT) levels could represent a new diagnostic biomarker for prostate cancer (PCa). In this study, we aimed to explore the diagnostic and prognostic/aggressiveness capacity of GOAT in urine, as well as to interrogate its putative pathophysiological role in PCa. We analysed urine/plasma levels of GOAT in a cohort of 993 patients. In vitro (i.e., cell-proliferation) and in vivo (tumor-growth in a xenograft-model) approaches were performed in response to the modulation of GOAT expression/activity in PCa cells. Our results demonstrate that plasma and urine GOAT levels were significantly elevated in PCa patients compared to controls. Remarkably, GOAT significantly outperformed PSA in the diagnosis of PCa and significant PCa in patients with PSA levels ranging from 3 to 10 ng/mL (the so-called PSA grey-zone). Additionally, urine GOAT levels were associated to clinical (e.g., Gleason-score, PSA levels) and molecular (e.g., CDK2/CDK6/CDKN2A expression) aggressiveness parameters. Indeed, GOAT overexpression increased, while its silencing/blockade decreased cell-proliferation in PCa cells. Moreover, xenograft tumors derived from GOAT-overexpressing PCa (DU145) cells were significantly higher than those derived from the mock-overexpressing cells. Altogether, our results demonstrate that GOAT could be used as a diagnostic and aggressiveness marker in urine and a therapeutic target in PCa.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceJournal of Clinical Medicine 8(12), 2056 (2019)es_ES
dc.subjectGOAT-enzymees_ES
dc.subjectProstate canceres_ES
dc.subjectDiagnosises_ES
dc.subjectTherapyes_ES
dc.subjectPSAes_ES
dc.titleClinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.3390/jcm8122056es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI16/00264es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI17-02287es_ES
dc.relation.projectIDInstituto de Salud Carlos III. CM16/00180es_ES
dc.relation.projectIDGobierno de España. BFU2016-80360-Res_ES
dc.relation.projectIDGobierno de España. FPU18/02485es_ES
dc.relation.projectIDGobierno de España. FPU16/06190es_ES
dc.relation.projectIDJunta de Andalucía. BIO-0139es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record